Delaware’s ophthalmologists will have a chance to get their hands on a new device designed to replace the old one, which they will have to take apart and reassemble.
The device, called the LaserEyebrow, is designed to help patients with macular degeneration, a degenerative eye condition.
But it won’t replace the current treatment for this condition, which involves removing the retina, or eye, and replacing it with a new one.
The technology is still being developed, and the FDA will issue a final regulatory decision next month.
Here’s how the LaserEye works.
The LaserEyewear’s lid is filled with liquid to prevent the liquid from getting in the eye.
The lid is pressed against the cornea to hold it in place.
A laser is shone into the corneal cavity, causing a reaction that releases the eye’s fluid.
The liquid in the lid is then replaced with a solution of saline and hydrocortisone.
The new lens is then placed over the old, which contains the fluid that was removed from the eye before the treatment.
A small tube is inserted into the tube and attached to the lid.
The ophthalmic surgeon will remove the old lid and replace it with the new one using an adhesive called a microfiber gel.
After surgery, the eye will be cleaned using an eye wash and a sterile saline solution.
The eye can be reattached with a laser, or it can be removed with a small screwdriver, depending on the severity of the condition.
A few people with degenerative macular disease have difficulty with the lid, but the procedure is typically very quick and painless.
The FDA plans to make a final decision on whether the laserEyewears use the same laser as existing treatments sometime next month, and is expected to announce whether or not it will be approved.
Here are some other medical conditions patients can have: 1.
Ophthalmological conditions: Macular degenerative glaucoma, cataract surgery, glauco-pallidum and cataracts 2.
Ocular conditions: retinal detachment, cataryngology, cataplexy, retinal vein diseases, retinitis pigmentosa, retinoschisis, and other conditions related to retinal injury 3.
Other conditions: neuropathy, peripheral neuropathy and stroke 4.
Oculopathies: ocular, ocular and central optic, and optic nerve disorders.
The company also recently raised $20 million in a Series B round led by UBS and Fidelity Investments.
Delware’s CEO, Chris Smith, told Fortune the company is looking for investors with high levels of net worth and small to medium sized companies with a minimum of $1 billion in sales.